Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for TELA Bio, Inc. (TELA : NSDQ)

• Company Description    TELA Bio Inc. is a commercial stage medical technology company. It is focused on the designing, developing and marketing of tissue reinforcement materials to address unmet needs in soft tissue reconstruction. The company offers a portfolio of advanced reinforced tissue matrices. TELA Bio Inc. is headquartered in Malvern, Pennsylvania. Number of Employees: 150

• Price / Volume Information    Yesterday's Closing Price: $0.89 Daily Weekly Monthly 20 Day Moving Average: 265,375 shares Shares Outstanding: 44.77 (millions) Market Capitalization: $39.85 (millions) Beta: 1.30 52 Week High: $2.20 52 Week Low: $0.50 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 43.10% 36.11% 12 Week 8.83% 0.61% Year To Date -24.57% -28.12%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 1 GREAT VALLEY PARKWAY SUITE 24 - MALVERN,PA 19355 USA ph: 484-320-2930 fax: - ir@telabio.com http://www.telabio.com

• General Corporate Information    Officers Antony Koblish - Chief Executive Officer and Director Doug Evans - Chairman; Board of Directors Roberto Cuca - Chief Operating Officer and Chief Financial Office Megan Smeykal - Chief Accounting Officer and Controller Kurt Azarbarzin - Director Peer Information TELA Bio, Inc. (CORR.) TELA Bio, Inc. (RSPI) TELA Bio, Inc. (CGXP) TELA Bio, Inc. (BGEN) TELA Bio, Inc. (GTBP) TELA Bio, Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 872381108 SIC: 3841 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/26 Next Expected EPS Date: 08/10/26 Share - Related Items Shares Outstanding: 44.77 Most Recent Split Date: (:1) Beta: 1.30 Market Capitalization: $39.85 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.17 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-0.69 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 1.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/10/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: - Price/Cash Flow: - Price / Sales: 0.49 EPS Growth vs. Year Ago Period: 16.00% vs. Previous Quarter: -31.25% Sales Growth vs. Year Ago Period: 2.91% vs. Previous Quarter: -8.67% ROE 03/31/26 - -1,320.81 12/31/25 - -433.58 09/30/25 - -272.13 ROA 03/31/26 - -55.83 12/31/25 - -53.00 09/30/25 - -53.25 Current Ratio 03/31/26 - 3.61 12/31/25 - 4.20 09/30/25 - 3.30 Quick Ratio 03/31/26 - 2.92 12/31/25 - 3.59 09/30/25 - 2.62 Operating Margin 03/31/26 - -48.43 12/31/25 - -47.50 09/30/25 - -50.61 Net Margin 03/31/26 - -49.30 12/31/25 - -48.37 09/30/25 - -50.61 Pre-Tax Margin 03/31/26 - -49.00 12/31/25 - -48.09 09/30/25 - -50.69 Book Value 03/31/26 - -0.12 12/31/25 - 0.16 09/30/25 - 0.04 Inventory Turnover 03/31/26 - 2.26 12/31/25 - 2.15 09/30/25 - 2.02 Debt-to-Equity 03/31/26 - - 12/31/25 - 8.82 09/30/25 - 26.65 Debt-to-Capital 03/31/26 - - 12/31/25 - 89.81 09/30/25 - 96.38

Powered by Zacks Investment Research ©